Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 9, Issue 6, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac064
Keywords
B-cell-depleted; monoclonal antibodies; prolonged SARS-CoV-2
Categories
Funding
- HIV Prevention Trials Network (HPTN) - National Institute of Allergy and Infectious Diseases (NIAID) of the NIH, DHHS [UM1 AI068613]
- National Institute on Drug Abuse of the NIH, DHHS [UM1 AI068613]
- National Institute of Mental Health of the NIH, DHHS [UM1 AI068613]
- Office of AIDS Research, of the NIH, DHHS [UM1 AI068613]
- NIH RADx-Tech program [3U54HL143541-02S2]
- National Institute of Health RADx-UP initiative [R01DA045556-04S1]
- National Institute of Allergy and Infectious Diseases (Johns Hopkins Center of Excellence in Influenza Research and Surveillance) [HHSN272201400007C]
- Johns Hopkins University President's Fund Research Response
- Johns Hopkins Department of Pathology
- Maryland Department of Health
- CDC
Ask authors/readers for more resources
B-cell-depleted patients with prolonged COVID-19 infection, caused by the inability to generate sufficient humoral response to clear the virus, were successfully treated with a combination of casirivimab/imdevimab and remdesivir.
Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
